source
- Eli Lilly to acquire AtaiBeckley in up to $3.8 billion deal, entering psychedelics marketEli Lilly announced it will buy AtaiBeckley, offering $6.75 per share for the company’s common stock. The transaction includes an upfront commitment of about $2.8 billion and a contingent value rig…
- Takeda's zasocitinib clears scalp psoriasis in 75% of patients in phase 3 dataTakeda released updated results from its two phase 3 trials of the oral TYK2 inhibitor zasocitinib, enrolling a total of 1,801 patients with moderate-to-severe plaque psoriasis. The data showed th…